Besides hyperproliferation, the action of EMT‐TFs on the p53 pathway can provide chemoresistance to CAFs, an event that likely promotes CAF survival and subsequent CAF‐facilitated tumour resistance during anticancer therapies. The gene discussed is TP53; the disease is neoplasm.